Hudson Bay Capital Management LP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAB5. A total of 1 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Hudson Bay Capital Management LP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$9,241,631
+40.3%
3,867,0000.0%0.10%
+63.8%
Q3 2022$6,587,000
-12.5%
3,867,000
-3.3%
0.06%
+1.8%
Q2 2022$7,530,000
+8.6%
4,000,0000.0%0.06%
-39.4%
Q1 2022$6,931,000
+12.9%
4,000,000
+14.3%
0.09%
+51.6%
Q4 2021$6,138,000
+72.3%
3,500,000
+75.0%
0.06%
+29.2%
Q3 2021$3,562,0002,000,0000.05%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
WOLVERINE ASSET MANAGEMENT LLC 33,098,000$57,663,0000.54%
TENOR CAPITAL MANAGEMENT Co., L.P. 12,750,000$22,298,0000.47%
PALISADE CAPITAL MANAGEMENT, LP 2,000,000$3,522,0000.07%
Calamos Advisors LLC 10,000,000$17,559,0000.07%
Hudson Bay Capital Management LP 3,500,000$6,138,0000.06%
D. E. Shaw & Co., Inc. 17,444,000$30,383,0000.02%
BNP PARIBAS FINANCIAL MARKETS 3,752,000$6,588,286,0000.01%
ADVENT CAPITAL MANAGEMENT /DE/ 115,000$203,0000.00%
JPMORGAN CHASE & CO 3,316,000$5,854,0000.00%
SUSQUEHANNA INTERNATIONAL GROUP, LLP 3,686,000$6,414,0000.00%
View complete list of HALOZYME THERAPEUTICS INC shareholders